rs587781433
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Breast cancer-derived T58A MYC mutations are unable to activate Bim due to their failure to regulate p14/p21.
|
30655867 |
2019 |
rs587781858
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
rs78378222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Five variants were previously reported to confer risk of various malignant or benign tumors (rs78378222 in TP53, rs10069690 in TERT, rs1800057 and rs1801516 in ATM, and rs7907606 at OBFC1) and four signals are located at established risk loci for hormone-related traits (endometriosis and breast cancer) at 1q36.12 (CDC42/WNT4), 2p25.1 (GREB1), 20p12.3 (MCM8), and 6q26.2 (SYNE1/ESR1).
|
30194396 |
2018 |
rs587780071
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We previously demonstrated that this estrogen-MDM2 axis activates the proliferation of breast cancer cell lines T47D (mtp53 L194F) and MCF7 (wild-type p53) in a manner independent of increased degradation of wild-type p53 (ie, p53-independently).
|
28615518 |
2017 |
rs587782596
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TP53 p.R181C predisposed specifically to breast cancer</span> with incomplete penetrance, and not to other Li-Fraumeni cancers.
|
28486781 |
2017 |
rs876660825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers.
|
28499267 |
2017 |
rs1057520006
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
rs760043106
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed the association between p.</span>I157T and the clinico-pathological breast cancer characteristics by comparing the p.I157T carrier tumors to non-carrier and c.1100delC carrier tumors.
|
27716369 |
2016 |
rs1064794312
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The targeted screen also uncovered a new TP53 mutation, c.685T>C [p.Cys229Arg] that was found in two breast cancer cases.
|
25925845 |
2015 |
rs1159579789
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The G473A polymorphism (rs1800449) results in the Arg158Gln amino acid substitution in the LOX propeptide, compromises its tumour suppressive activity, and was associated with an increased breast cancer risk in a Chinese Han population.
|
25141126 |
2014 |
rs2287499
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Concisely, no significant overall associations between rs2287499 and breast cancer risk and prognosis were detected in the studied population.
|
25134915 |
2014 |
rs55819519
|
|
|
0.010 |
GeneticVariation |
BEFREE |
LOX mRNA expression was significantly elevated in tumours of patients older than 55 years, postmenopausal patients, estrogen receptor positive tumours, and p53 negative tumours, but was unaffected by G473A genotype in tumours and breast cancer cell lines.
|
25141126 |
2014 |
rs587782144
|
|
|
0.010 |
GeneticVariation |
BEFREE |
LOX mRNA expression was significantly elevated in tumours of patients older than 55 years, postmenopausal patients, estrogen receptor positive tumours, and p53 negative tumours, but was unaffected by G473A genotype in tumours and breast cancer cell lines.
|
25141126 |
2014 |
rs121913343
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
rs1800371
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The p53 variant Pro47Ser was detected only in one Kuwaiti breast cancer patient and was not detected in any of the control subjects.
|
20443084 |
2011 |
rs1457582183
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer.
|
20082851 |
2010 |
rs1177881399
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The D153G substitution only partially segregated with breast cancer in the family and was not identified on additional 680 chromosomes screened.
|
18279506 |
2008 |
rs1288373809
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.
|
18416817 |
2008 |
rs375275361
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We find that a homozygous common missense variant (NQO1(*)2, rs1800566(T), NM_000903.2:c.558C>T) that disables NQO1 strongly predicts poor survival among two independent series of women with breast cancer (P = 0.002, N = 1,005; P = 0.005, N = 1,162), an effect particularly evident after anthracycline-based adjuvant chemotherapy with epirubicin (P = 7.52 x 10(-6)) and in p53-aberrant tumors (P = 6.15 x 10(-5)).
|
18511948 |
2008 |
rs375874539
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.
|
18416817 |
2008 |
rs587782646
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the Ex4 + 19 C > G SNP (rs1042522), women with the heterozygous genotype (G/C) had a 32% increase in breast cancer risk.
|
17624591 |
2008 |
rs762846821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The D153G substitution only partially segregated with breast cancer in the family and was not identified on additional 680 chromosomes screened.
|
18279506 |
2008 |
rs1057519981
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The tightly linked intronic ATM polymorphisms IVS22-77 T>C and IVS48 + 238 C>G, in the homozygote state were associated with increased BC risk [IVS22-77 CC versus TT odds ratio (OR), 1.67; 95% confidence interval (CI), 1.00-2.81], and in the heterozygote state with clinical radioprotection (IVS22-77 CT versus TT OR, 0.45; 95% CI, 0.24-0.85).
|
14695186 |
2003 |
rs1057520001
|
|
|
0.020 |
GeneticVariation |
BEFREE |
P21 Ser31Arg and FGFR2 rs2981582 Polymorphisms as Risk Factors for Early Onset of Breast Cancer in Yogyakarta, Indonesia.
|
31759353 |
2019 |
rs886039484
|
|
|
0.020 |
GeneticVariation |
BEFREE |
P21 Ser31Arg and FGFR2 rs2981582 Polymorphisms as Risk Factors for Early Onset of Breast Cancer in Yogyakarta, Indonesia.
|
31759353 |
2019 |